CMS
CRSP icon

Capital Market Strategies’s CRISPR Therapeutics CRSP Stock Holding History

Capital Market Strategies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$988K Sell
20,310
-1,057
-5% -$40.9K 0.69% 32
2025
Q1 		$727K Buy
21,367
+9,652
+82% +$409K 0.49% 43
2024
Q4 		$461K Buy
+11,715
New +$553K 0.27% 81

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Market Strategies's CRSP Position: Q2 2025 in Review

Capital Market Strategies reduced its CRISPR Therapeutics (CRSP) stake by 4.9% in Q2 2025, selling an estimated $40.9K and leaving 20,310 shares worth $988K. The position accounts for 0.69% of the portfolio, ranked #32.

Capital Market Strategies first reported a position in CRSP in Q4 2024 and has held it in 3 quarters since. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Capital Market Strategies held 20,310 shares of CRISPR Therapeutics worth $988K as of Q2 2025.
  • Capital Market Strategies sold 1,057 CRISPR Therapeutics shares in Q2 2025, an estimated $40.9K.
  • CRISPR Therapeutics made up 0.69% of Capital Market Strategies's portfolio in Q2 2025, its #32 holding.
  • Capital Market Strategies first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Capital Market Strategies's 13F filing for Q2 2025, filed 2 Jul 2025.